Table 1.
Study Sample Characteristics (N=3,643)*
| Time from Definitive Surgery to Chemotherapy | ||||||
|---|---|---|---|---|---|---|
| Early** (N = 2,454) | Late^ (N = 186) | No Chemotherapy (N = 1,003) | ||||
| N | (Row %) | N | (Row %) | N | (Row %) | |
| Type of Surgery | ||||||
| Mastectomy with Immediate Reconstruction | 446 | (74.8) | 53 | (8.9) | 97 | (16.3) |
| Breast Conserving Surgery | 1387 | (64.4) | 91 | (4.2) | 677 | (31.4) |
| Mastectomy alone | 534 | (67.4) | 39 | (4.9) | 219 | (27.7) |
| Mastectomy with Delayed Reconstruction | 87 | (87.0) | 3 | (3.0) | 10 | (10.0) |
| Patient Age at Diagnosis | ||||||
| <40 | 402 | (89.7) | 22 | (4.9) | 24 | (5.4) |
| 40–49 | 901 | (83.3) | 58 | (5.4) | 123 | (11.4) |
| 50–59 | 725 | (74.4) | 53 | (5.4) | 197 | (20.2) |
| ≥60 | 426 | (37.4) | 53 | (4.7) | 659 | (57.9) |
| Stage at Diagnosis | ||||||
| Stage I | 659 | (49.1) | 53 | (3.9) | 630 | (46.9) |
| Stage II | 1730 | (77.9) | 127 | (5.7) | 365 | (16.4) |
| Stage III | 65 | (82.3) | 6 | (7.6) | 8 | (10.1) |
| Path Tumor Size | ||||||
| ≤2 cm | 1348 | (60.6) | 103 | (4.6) | 773 | (34.8) |
| >2–5 cm | 981 | (78.4) | 72 | (5.8) | 198 | (15.8) |
| >5 cm | 84 | (80.0) | 7 | (6.7) | 14 | (13.3) |
| Unknown/missing | 41 | (65.1) | 4 | (6.3) | 18 | (28.6) |
| Number of Positive Nodes | ||||||
| 0 | 1106 | (57.4) | 88 | (4.6) | 734 | (38.1) |
| 1–3 | 1019 | (78.6) | 70 | (5.4) | 208 | (16.0) |
| 4–9 | 226 | (83.4) | 21 | (7.7) | 24 | (8.9) |
| 10 or more | 99 | (86.1) | 7 | (6.1) | 9 | (7.8) |
| N/A | 4 | (12.5) | 0 | (0.0) | 28 | (87.5) |
| Race/Ethnicity | ||||||
| Caucasian | 2052 | (67.0) | 155 | (5.1) | 854 | (27.9) |
| Hispanic | 138 | (71.1) | 13 | (6.7) | 43 | (22.2) |
| African-American | 176 | (66.7) | 13 | (4.9) | 75 | (28.4) |
| Other | 88 | (71.0) | 5 | (4.0) | 31 | (25.0) |
| Median Household Income (quartiles) | ||||||
| Q1: $0–<$35,426 | 562 | (63.9) | 50 | (5.7) | 267 | (30.4) |
| Q2: $35,426–<$44,639 | 582 | (66.2) | 58 | (6.6) | 239 | (27.2) |
| Q3: $44,639–<$58,844 | 588 | (66.9) | 47 | (5.3) | 244 | (27.8) |
| Q4: $58,844–$159,538 | 632 | (71.8) | 27 | (3.1) | 221 | (25.1) |
| Foreigner | 26 | (81.3) | 2 | (6.3) | 4 | (12.5) |
| Unknown | 64 | (68.1) | 2 | (2.1) | 28 | (29.8) |
| Comorbidity Score | ||||||
| 0 | 2091 | (71.1) | 148 | (5.0) | 701 | (23.8) |
| 1 | 265 | (54.9) | 28 | (5.8) | 190 | (39.3) |
| ≥2 | 98 | (44.5) | 10 | (4.5) | 112 | (50.9) |
| Body Mass Index | ||||||
| < 25 kg/m2 | 1050 | (72.6) | 49 | (3.4) | 348 | (24.0) |
| 25–35 kg/m2 | 1036 | (64.4) | 90 | (5.6) | 483 | (30.0) |
| >35 kg/m2 | 252 | (63.2) | 36 | (9.0) | 111 | (27.8) |
| Unknown | 116 | (61.7) | 11 | (5.9) | 61 | (32.4) |
| Type of Reconstruction | ||||||
| No Reconstruction | 1921 | (65.2) | 130 | (4.4) | 896 | (30.4) |
| Implant | 264 | (76.3) | 20 | (5.8) | 62 | (17.9) |
| Pedicle TRAM flap | 105 | (81.4) | 17 | (13.2) | 7 | (5.4) |
| Free TRAM flap | 115 | (74.7) | 12 | (7.8) | 27 | (17.5) |
| Other rotational flap | 37 | (72.5) | 5 | (9.8) | 9 | (17.6) |
| Other free flap | 12 | (75.0) | 2 | (12.5) | 2 | (12.5) |
| Institution | ||||||
| A | 111 | (66.5) | 11 | (6.6) | 45 | (26.9) |
| B | 443 | (73.2) | 24 | (4.0) | 138 | (22.8) |
| C | 259 | (65.6) | 40 | (10.1) | 96 | (24.3) |
| D | 415 | (62.5) | 30 | (4.5) | 219 | (33.0) |
| E | 263 | (63.2) | 18 | (4.3) | 135 | (32.5) |
| F | 168 | (76.7) | 3 | (1.4) | 48 | (21.9) |
| G | 386 | (70.1) | 32 | (5.8) | 133 | (24.1) |
| H | 409 | (65.3) | 28 | (4.5) | 189 | (30.2) |
| Guideline | ||||||
| Stage I/II node negative, Tubular/Colloid, Tumor Size >=3 cm | 3 | (33.3) | 0 | (0.0) | 6 | (66.7) |
| Stage I/II node negative, HR negative, Tumor Size > 1 cm | 427 | (78.3) | 38 | (7.0) | 80 | (14.7) |
| Stage I/II node negative, HR positive, Tumor Size >1–3 cm | 602 | (46.7) | 41 | (3.2) | 645 | (50.1) |
| Stage I/II node negative, HR positive, Tumor Size >3 cm | 78 | (67.2) | 9 | (7.8) | 29 | (25.0) |
| Stage I/II node positive, HR negative | 335 | (85.7) | 28 | (7.2) | 28 | (7.2) |
| Stage I/II node positive, HR positive | 944 | (77.7) | 64 | (5.3) | 207 | (17.0) |
| Stage IIIA with T3N1 | 65 | (82.3) | 6 | (7.6) | 8 | (10.1) |
*
Newly diagnosed Stage I, II, and III BCA patients who presented at NCCN institution from July 30, 1997 to December 31, 2003, received definitive surgery, and were recommended to receive adjuvant chemotherapy based on NCCN guidelines (v. 1997 – v. 2003).
**
Early delivery of chemotherapy is receipt less than 8 weeks from definitive surgery
^
Late delivery of chemotherapy is receipt 8 weeks or more from definitive surgery